Standout Papers

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with... 2017 2026 2020 2023 379
  1. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer (2017)
    Stephen Bagley, Shawn Kothari et al. Lung Cancer

Immediate Impact

2 by Nobel laureates 3 from Science/Nature 70 standout
Sub-graph 1 of 23

Citing Papers

Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
2 intermediate papers

Works of John A. Kosteva being referenced

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
2017 Standout

Author Peers

Author Last Decade Papers Cites
John A. Kosteva 406 194 49 71 11 459
Munehiro Ito 476 312 31 79 13 533
Victoria Sherry 383 172 25 71 14 429
Shawn Kothari 398 172 45 93 12 514
Changli Wang 370 101 73 149 16 444
R. Blanco 271 177 40 36 11 448
Prabhu Bhagavatheeswaran 380 299 81 91 13 452
Idoia Morilla 339 122 41 172 17 435
Kyoji Tsurumi 481 226 13 102 10 518
Maria Cristina Bruna 234 254 33 97 13 471
Keisuke Terayama 480 224 12 102 10 518

All Works

Loading papers...

Rankless by CCL
2026